Gilead Sciences, Inc. (GILD), a Drug Manufacturers—General business, was a gaining stock in the previous trading session. Gilead Sciences, Inc. (GILD) shares started the day for trading at $77.10 and closed the day at $79.64 with momentum of +2.39%. The increase move in Gilead Sciences, Inc. (GILD) beat the move in the S&P 500 for the day which gained +1.39% in previous trading day.
Gilead Sciences, Inc. (GILD) is focused on the Drug Manufacturers—General sector. This sector has seen some movement from investors in recent months. Bullish investors of Gilead Sciences, Inc. (GILD) will be looking for positive upcoming earnings whereas bearish investors of Gilead Sciences, Inc. (GILD) will be looking for negative earnings. The last time Gilead Sciences, Inc. (GILD) had an earnings surprise was on Qtr Ending 12/19 when they reported $1.10 compared to an estimate of $1.58 which was a difference of -$0.48 resulting in a change of -30.38%. Current earnings estimates are to be released for Current Qtr 03/2020 on Gilead Sciences, Inc. (GILD) and out of 7 Wall Street estimates the average is saying $1.47. The high estimate is saying $1.74 whereas the low estimate is saying $1.33 and the prior year Gilead Sciences, Inc. (GILD) announced earnings at $1.67 a growth rate est. (year over year) of -11.98%.
The market performance of Gilead Sciences, Inc. (GILD) has varied recently. Year to date Gilead Sciences, Inc. (GILD)’s shares are up 22.56%. Over the past 12 weeks Gilead Sciences, Inc. (GILD) is up 24.38% and over the last 4 weeks Gilead Sciences, Inc. (GILD) is up 7.83%. Gilead Sciences, Inc. (GILD) current income statement shows revenue (ttm) of $22.45B. Gross Profit is $17.77B. This puts the current EBITDA of Gilead Sciences, Inc. (GILD) at $6.49B.
Wall street investors might also notice recent changes to stock analyst estimates for Gilead Sciences, Inc. (GILD). The stock is trading with an RSI (relative strength index) of 53.72 indicating Gilead Sciences, Inc. (GILD) is neither overbought nor oversold. Technically, GILD’s short term support levels are around $79.27, $78.28 and $77.36 on the downside. GILDs short term resistance levels are $85.17, $80.98 and $80.27 on the upside. The market cap of Gilead Sciences, Inc. (GILD) is $100.268B and institutions hold 84.00% of the stock. The outstanding share count stands at 1.32B while the short float (shares short) stands at 1.80%.
Stock market research indicates that these earning estimate changes look to be directly correlated with short-term shares prices. The investors can look to capitalize on the basis of ranking. Gilead Sciences, Inc. (GILD) has short term rating of Bullish (0.28), Intermediate rating of Bullish (0.29) and long-term rating of Bullish (0.44) giving Gilead Sciences, Inc. (GILD) an overall rating of Bullish (0.34).
The EPS growth this year on Gilead Sciences, Inc. (GILD) is increased 1.10% and is expected to increase 0.32% next year. However, quarterly earnings (EPS) growth year over year on Gilead Sciences, Inc. (GILD) has increased by 89766.70% and quarterly revenue (Sales) growth year over year stands at 1.40%. Gross margin is detected at 79.20% that represents the percent of total sales revenue that the company retains after direct cost of goods sold. Net profit margin (ttm) is 24.00% while return on equity (ttm) is 24.60%.
2020-04-23 – Gilead Says Regrets That WHO Prematurely Posted Data Regarding Remdesivir Study.
2020-04-23 – Gilead Antiviral Drug Remdesivir Flops In First Trial – FT.
2020-04-06 – Gilead Sciences And Second Genome Announce Collaboration In Biomarker And Inflammatory Bowel Disease Drug Discovery.
2020-04-05 – Gilead Sciences Says Taking Actions Since January To Rapidly Expand Production, Supply Of Investigational Drug Remdesivir.
2020-03-30 – Gilead Announces Expiration Of Hart-Scott-Rodino Waiting Period For Forty Seven Tender Offer.
Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide (TAF)-based products Genvoya, Odefsey, Descovy, Biktarvy and Truvada. Total sales from HIV franchise came in at $16.